Roche amyloid plasma panel designated a breakthrough device

Create PDF

Roche received a breakthrough device designation in 2018 for the Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF in vitro diagnostic immunoassays measuring beta-amyloid (1-42) and phospho-tau concentrations in cerebrospinal fluid in adult patients with cognitive impairment who are being evaluated for Alzheimer disease or other causes of dementia